Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.
作者信息
Bradberry Mazdak M, Gukasyan Natalie, Raison Charles L
机构信息
Department of Neuroscience, University of Wisconsin School of Medicine and Public Health, Madison.
Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison.
出版信息
JAMA Psychiatry. 2022 Jun 1;79(6):525-527. doi: 10.1001/jamapsychiatry.2022.0665.
Abstract
摘要
相似文献
1
Toward Risk-Benefit Assessments in Psychedelic- and MDMA-Assisted Therapies.迈向迷幻剂和摇头丸辅助疗法的风险效益评估。
JAMA Psychiatry. 2022 Jun 1;79(6):525-527. doi: 10.1001/jamapsychiatry.2022.0665.
2
Compassionate use of psychedelics.同情用药的致幻剂。
Med Health Care Philos. 2020 Sep;23(3):485-496. doi: 10.1007/s11019-020-09958-z.
3
Is there a case for MDMA-assisted psychotherapy in the UK?在英国，MDMA辅助心理治疗有存在的理由吗？
J Psychopharmacol. 2007 Mar;21(2):220-4. doi: 10.1177/0269881107069029.
4
Common side effects of MDMA-assisted psychotherapy.摇头丸辅助心理治疗的常见副作用。
Neuropsychopharmacology. 2024 Jul;49(8):1206-1207. doi: 10.1038/s41386-024-01873-8. Epub 2024 May 13.
5
The potential dangers of using MDMA for psychotherapy.使用 MDMA 进行心理治疗的潜在危险。
J Psychoactive Drugs. 2014 Jan-Mar;46(1):37-43. doi: 10.1080/02791072.2014.873690.
6
MDMA (Ecstasy) use and psychiatric problems.摇头丸（摇头丸）的使用与精神问题。
Psychopharmacology (Berl). 2007 Jan;189(4):575-6. doi: 10.1007/s00213-006-0606-x. Epub 2006 Oct 24.
7
Can MDMA play a role in the treatment of substance abuse?摇头丸能在药物滥用治疗中发挥作用吗？
Curr Drug Abuse Rev. 2013 Mar;6(1):54-62. doi: 10.2174/18744737112059990005.
8
Reply to: Caution at psychiatry's psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy.回复：精神病学迷幻前沿的注意事项以及摇头丸辅助心理治疗的基准挑战。
Nat Med. 2021 Oct;27(10):1691-1692. doi: 10.1038/s41591-021-01526-z. Epub 2021 Oct 11.
9
A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.在治疗抵抗性 PTSD 中，将 MDMA 辅助心理治疗与非辅助心理治疗进行比较：系统评价和荟萃分析。
J Psychopharmacol. 2021 May;35(5):501-511. doi: 10.1177/0269881120965915. Epub 2020 Dec 20.
10
MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.在一小群患有慢性创伤后应激障碍的女性中使用低剂量摇头丸辅助心理治疗。
J Psychoactive Drugs. 2008 Sep;40(3):225-36. doi: 10.1080/02791072.2008.10400637.
引用本文的文献
1
Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report.居家治疗环境中用于姑息治疗的迷幻剂辅助疗法：一例报告
Clin Case Rep. 2024 Aug 30;12(9):e9305. doi: 10.1002/ccr3.9305. eCollection 2024 Sep.
2
Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca.仪式用致幻剂下的创伤后再体验不良生活事件的流行率和治疗效果。
Sci Rep. 2023 Jun 9;13(1):9438. doi: 10.1038/s41598-023-36184-3.
3
Psychedelic Drug Legislative Reform and Legalization in the US.美国迷幻药立法改革与合法化。
JAMA Psychiatry. 2023 Jan 1;80(1):77-83. doi: 10.1001/jamapsychiatry.2022.4101.
4
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.支持公平获取负责任、可问责、安全和符合伦理的迷幻药物使用的政策考虑因素。
Neuropharmacology. 2022 Nov 15;219:109214. doi: 10.1016/j.neuropharm.2022.109214. Epub 2022 Aug 13.
5
Brain Wellness "Spas"-Anticipating the Off-label Promotion of Psychedelics.大脑健康“水疗中心”——对迷幻药的非标签推广的预期。
JAMA Psychiatry. 2022 Aug 1;79(8):748-749. doi: 10.1001/jamapsychiatry.2022.1619.
本文引用的文献
1
Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.评估经典迷幻剂的风险效益比：第二波迷幻剂研究的临床综述。
Psychopharmacology (Berl). 2022 Jun;239(6):1907-1932. doi: 10.1007/s00213-021-06049-6. Epub 2022 Jan 13.
2
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.接受 MDMA 辅助心理治疗的 PTSD 患者的长期随访结果：6 项 2 期试验的纵向合并分析。
Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4.
3
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.在患有慢性、治疗抵抗性创伤后应激障碍的受试者中，3,4-亚甲二氧基甲基苯丙胺辅助心理治疗的安全性和有效性：首个随机对照初步研究。
J Psychopharmacol. 2011 Apr;25(4):439-52. doi: 10.1177/0269881110378371. Epub 2010 Jul 19.
4
Human hallucinogen research: guidelines for safety.人类致幻剂研究：安全指南。
J Psychopharmacol. 2008 Aug;22(6):603-20. doi: 10.1177/0269881108093587. Epub 2008 Jul 1.
5
Prolonged adverse reactions to lysergic acid diethylamide.麦角酸二乙酰胺的长期不良反应。
Arch Gen Psychiatry. 1963 May;8:475-80. doi: 10.1001/archpsyc.1963.01720110051006.
6
Adverse reactions to psychedelic drugs. A review of the literature.致幻药物的不良反应。文献综述。
J Nerv Ment Dis. 1984 Oct;172(10):577-95. doi: 10.1097/00005053-198410000-00001.
Zotero 插件